What Is Signatera Testing and How Does It Work?

Signatera is a blood test designed to detect tiny traces of cancer DNA circulating in the bloodstream after a tumor has been surgically removed or treated. It works by first analyzing a patient’s own tumor tissue to identify a unique set of genetic mutations, then building a custom test that hunts specifically for those mutations in a simple blood draw. The goal is to catch cancer recurrence months before a scan would, and to help oncologists decide whether someone needs additional treatment like chemotherapy. It sits at the intersection of two rapidly growing fields: liquid biopsy and precision oncology, and its use is expanding across several cancer types.

How Tumor DNA Ends Up in Your Blood

To understand what Signatera is looking for, it helps to know that cancer cells constantly shed fragments of their DNA into the bloodstream. This happens when tumor cells die through natural processes or are killed by treatments, releasing their genetic material into circulation. These fragments are called circulating tumor DNA, or ctDNA, and they mix in with the much larger pool of normal cell-free DNA that all of your cells release as part of routine cell turnover.¹

The body clears these DNA fragments quickly. The half-life of cell-free DNA ranges from about 16 minutes to two and a half hours, with the liver doing the bulk of the cleanup work, followed by the kidneys.² That rapid turnover is actually useful: it means a blood sample gives you a near-real-time snapshot of what’s happening in the body right now, rather than a delayed picture. If cancer is present and actively shedding DNA, the test can pick it up. If it’s been eliminated, the signal disappears within hours.

Not all tumors shed DNA at the same rate, though. Some cancers release large amounts of ctDNA into the blood, while others produce barely detectable levels, and researchers still don’t fully understand why.³ This variability matters because it directly affects how sensitive any blood-based cancer test can be for a given patient.

Building a Personalized Test From Your Own Tumor

What makes Signatera different from many other ctDNA tests is its “tumor-informed” design. Rather than scanning the blood for a generic panel of cancer-related mutations, it starts by sequencing the patient’s own tumor tissue. The lab takes a sample of the surgically removed tumor (preserved in paraffin, the standard way hospitals store tissue) and performs whole exome sequencing to catalog the specific mutations present in that individual’s cancer. From this catalog, up to 16 unique mutations are selected to create a personalized test panel.⁴

Once the custom panel is built, the actual blood testing uses a technique called multiplex PCR followed by next-generation sequencing.⁵ In plain terms, the PCR step amplifies any of those 16 target mutations if they’re present in the blood sample, making even vanishingly small amounts detectable. The sequencing step then confirms whether what was amplified is genuinely tumor-derived. A blood sample is considered positive if at least two of the tracked mutations are detected, which helps guard against false alarms from random sequencing errors.

One important technical detail: the assay also filters out mutations linked to something called clonal hematopoiesis, a common phenomenon where blood-forming stem cells acquire mutations as people age. These age-related mutations have nothing to do with cancer but can trip up less sophisticated blood tests. By comparing against both the tumor tissue and a normal (germline) DNA sample, Signatera screens out these imposters and focuses only on mutations that genuinely came from cancer cells.⁶

Why the Tumor-Informed Approach Outperforms Generic Panels

There are two broad philosophies in ctDNA testing. Tumor-informed assays like Signatera build a custom test from the patient’s own tumor, as described above. Tumor-agnostic assays, by contrast, use a fixed panel of commonly mutated genes and look for those same mutations across all patients. The agnostic approach is simpler to deploy because it skips the tumor-sequencing step, but the trade-off is sensitivity.

A systematic review and meta-analysis comparing the two approaches in colorectal cancer found that tumor-informed assays detected residual disease with substantially higher sensitivity when patients were tested repeatedly over time: about 88% for tumor-informed tests versus roughly 60% for tumor-agnostic ones. Specificity, the ability to correctly identify patients who are cancer-free, was similar between the two approaches.⁷ A separate meta-analysis presented at the American Society of Clinical Oncology found very similar numbers, with tumor-informed assays reaching 88% sensitivity versus 62% for tumor-agnostic tests in serial sampling.⁸

The practical implication is straightforward: if there’s residual cancer lurking after surgery, a tumor-informed test is more likely to find it. Both approaches are equally good at confirming the absence of disease, meaning false positives are rare regardless of which type of test you use. The sensitivity gap matters most for the core use case of Signatera: catching microscopic disease that hasn’t yet grown large enough to appear on a CT scan or MRI.

Detecting Cancer Recurrence Before Scans Can See It

The most compelling feature of Signatera testing is its ability to flag a recurrence months before conventional imaging picks it up. In a study of breast cancer patients who were monitored with personalized Signatera assays after surgery, ctDNA positivity preceded clinical or radiologic confirmation of relapse in 30 out of 34 patients who eventually recurred, giving a patient-level sensitivity of about 88%. The median lead time was 10.5 months, with some patients getting a signal up to 38 months before imaging showed anything.⁹

In colorectal cancer, similar dynamics play out. A case series confirmed that ctDNA-based molecular recurrence preceded imaging-detected recurrence in all patients examined, with a median lead time of about three months.¹⁰ Other research comparing single-target and multi-target ctDNA approaches in stage II and III colorectal cancer patients found lead times of around four months ahead of standard radiology.¹¹

That window of advance warning matters because it gives oncologists a chance to intervene earlier, whether through additional surgery, chemotherapy, or other treatments, before the cancer has had time to spread widely. Whether acting on an earlier signal actually translates into better long-term survival is one of the questions that ongoing clinical trials are designed to answer.

Where Signatera Is Being Used Across Cancer Types

Colorectal cancer is the most extensively studied setting for Signatera, but the test is being applied to a growing list of cancers. In stage II colorectal cancer, a retrospective analysis found that patients with negative ctDNA results after surgery had a 93% progression-free survival rate at 24 months, compared to 63% overall survival in those with positive results. Positive ctDNA status was a stronger predictor of poor outcomes than traditional risk factors like tumor stage alone.¹²

In pancreatic cancer, one of the most aggressive and difficult-to-treat malignancies, a study of patients who had completed curative-intent therapy found that those with positive ctDNA had dramatically shorter recurrence-free survival: a median of 3.6 months versus 29 months for ctDNA-negative patients. The specificity was 100%, meaning no patient who was truly cancer-free got a false positive result. However, sensitivity was lower at about 47%, meaning the test missed roughly half of the patients who eventually recurred.¹³ That lower sensitivity likely reflects the fact that some pancreatic tumors shed less DNA into the bloodstream, a known limitation across all ctDNA-based tests.

Studies have also explored Signatera in hepatocellular carcinoma (liver cancer), including in patients who have received liver transplants, as well as in head and neck squamous cell carcinoma and genitourinary cancers.⁴¹⁴ In advanced genitourinary cancers, researchers are studying whether tracking ctDNA levels over time can help assess how well immunotherapy is working, potentially providing a faster readout than waiting months for imaging.¹⁵

Guiding Chemotherapy Decisions

One of the most consequential applications of Signatera is helping oncologists decide who actually needs chemotherapy after surgery and who can safely skip it. This question is particularly acute in stage II colon cancer, where the overall recurrence risk is relatively low but the consequences of missing a recurrence are severe. Traditionally, doctors have relied on clinical and pathological features, like whether the tumor invaded nearby blood vessels or the number of lymph nodes sampled, to estimate risk. But these features are imprecise, and many patients end up getting chemotherapy they didn’t need.

The logic behind ctDNA-guided therapy is simple: if a patient’s blood shows no trace of tumor DNA after surgery, the cancer is likely gone and chemotherapy may be unnecessary. If ctDNA is detected, that’s a signal that microscopic cancer remains and additional treatment is warranted. Positive ctDNA status is now recognized as a strong prognostic factor for recurrence in cancer treatment guidelines and is emerging as a potential guide for adjuvant therapy decisions.¹⁶

Several randomized controlled trials are underway to formally test whether this approach improves outcomes. The CLAUDIA trial, for example, is investigating whether intensifying chemotherapy in colon cancer patients who test ctDNA-positive after surgery can reduce recurrence and improve survival.¹⁷ The TRACC trial is comparing ctDNA-guided adjuvant chemotherapy against standard-of-care treatment in high-risk stage II and stage III colorectal cancer, with disease-free survival at three years as its primary endpoint.¹⁸ Until these trials report mature results, the evidence is strongly suggestive but not yet definitive that ctDNA-guided decisions lead to better outcomes than conventional risk assessment alone.

Cost-Effectiveness

A cost-effectiveness analysis presented at ASCO examined what happens when you add ctDNA testing to the traditional clinical and pathological risk factors that oncologists already use to decide about chemotherapy in early-stage colorectal cancer. The results were encouraging: adding the test led to an estimated increase of 0.8 life years and 0.7 quality-adjusted life years per patient, along with cost savings of roughly $9,800 per patient compared to relying on conventional predictors alone.¹⁹ Those savings come largely from avoiding unnecessary chemotherapy courses in patients who don’t need them, since chemotherapy carries its own costs: the drugs themselves, infusion time, management of side effects, and lost productivity.

Insurance coverage for Signatera varies. As of this writing, Medicare covers it for certain colorectal cancer indications, and several private insurers have begun covering it as well, though coverage decisions are evolving as new clinical evidence accumulates. Patients should check with their oncologist and insurer about coverage for their specific cancer type and clinical situation.

What the Test Cannot Do

Signatera has real limitations that are worth understanding clearly. The most important one is that a negative result does not guarantee you are cancer-free. The pancreatic cancer data illustrate this starkly: sensitivity was under 50%, meaning more than half the patients who eventually recurred had negative ctDNA results at the time of testing. Even in cancer types where sensitivity is higher, like breast and colorectal cancer, a small percentage of recurrences will be missed. Some tumors simply don’t shed enough DNA into the blood to be detected, particularly small-volume or slow-growing cancers, or cancers in certain anatomical locations like the brain, where the blood-brain barrier limits DNA release into general circulation.

The test also requires tumor tissue to work. If no surgical sample or biopsy specimen is available, the personalized panel cannot be built. This limits its use to patients who have had a tissue sample collected at some point in their treatment.

Another subtle limitation involves confounders. Factors like active infections or certain medications can increase the total amount of cell-free DNA in the blood, which in theory could affect the fraction attributable to tumor-derived DNA and complicate interpretation. Researchers have cautioned that estimated ctDNA levels should be interpreted carefully when patients are undergoing radiation or chemotherapy, since inflammation and cell death from treatment can muddy the picture.²⁰ Signatera’s tumor-informed design mitigates this to some extent by tracking specific tumor mutations rather than overall DNA levels, but it’s still something clinicians factor into their interpretation.

The Psychological Side of Molecular Surveillance

Getting tested for cancer recurrence every few months carries an emotional weight that shouldn’t be overlooked. A qualitative study exploring how colorectal cancer survivors experience ctDNA testing found that results had a real impact on their psychological well-being, though not always in predictable ways. Patients who received negative results generally felt reassured, with one participant describing feeling “happy to know that there were no cancers.” But the experience of positive results was more complex: some patients described significant distress, while others found that the result validated their decision to pursue additional chemotherapy. Interestingly, many patients had limited recall of their specific ctDNA results, suggesting that the testing experience gets absorbed into the broader emotional landscape of cancer survivorship.²¹

Fear of cancer recurrence is already one of the most commonly reported concerns among cancer survivors, and adding a highly sensitive molecular surveillance tool to the mix introduces a new dimension. A negative result can provide powerful reassurance that scans alone cannot offer, since it’s checking for disease at a molecular level rather than waiting for something to grow large enough to photograph. But a positive result, especially when scans still look clean, can create a period of ambiguity that some patients find deeply unsettling. Oncologists increasingly recognize that counseling about what ctDNA results mean (and don’t mean) is an essential part of ordering the test.

How Signatera Fits Into the Broader Liquid Biopsy Landscape

Signatera is one tool in a growing family of liquid biopsy technologies. Beyond ctDNA, researchers are also studying circulating tumor cells (intact cancer cells that break away from a tumor and travel through the bloodstream) and extracellular vesicles (tiny membrane-bound packets that tumors release). Each approach captures different biological information. Circulating tumor cells, for instance, can provide data on protein expression and RNA activity that DNA fragments alone cannot, giving them a theoretical edge for certain applications.²² In practice, though, ctDNA analysis is the most clinically advanced of the liquid biopsy technologies, with Signatera among the most widely studied commercial assays.

Within the ctDNA space itself, Signatera competes with several other commercial and academic platforms. Some of these are tumor-agnostic (using fixed gene panels), while others are also tumor-informed but use different technical approaches to detect mutations. The choice of platform can depend on the cancer type, the clinical question being asked, the availability of tumor tissue, and what a particular institution has validated in its workflow. No single ctDNA test has been proven definitively superior across all cancers and all clinical scenarios, and the field is evolving rapidly as new data from ongoing trials come in.

The typical monitoring schedule for patients on Signatera involves blood draws every three months for the first two years after surgery, then every six months for up to five years.⁴ That cadence means the test isn’t just a one-time snapshot: it’s a serial monitoring tool, and its performance actually improves with repeated testing because a single negative draw might miss low-level shedding that a subsequent draw would catch. This serial design is part of why the sensitivity gap between tumor-informed and tumor-agnostic assays is widest in the serial sampling setting rather than at any single time point.